Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors
Status:
Recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
An ascending dose study in patients with solid tumors to evaluate the safety, tolerability,
pharmacodynamics and efficacy of APG-1387 in combination with toripalimab. A phase II study
of 3 cohorts will be included.